Zentalis Pharmaceuticals
New York
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical business dedicated to finding and developing small molecule medicines that target cancer's underlying biological pathways. It employs an integrated discovery engine to find targets and produce small molecule new chemical entities, or NCEs, with features that it believes could result in potentially distinct product profiles. Its pipeline includes two lead product candidates: ZN-c5, which is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer, and ZN-c3, which is being developed for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $896.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2023)
- Ticker: nasdaq:ZNTL
- Website: zentalis.com
- Phone: 212-433-3791
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/zentalis-pharmaceuticals-19828 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.